NORDEN Reports Strong Q3 Results
NORDEN's net profit increased to USD 54 million and full-year guidance was raised to USD 200-250 million, which should positively impact the stock.
OUR ANALYSIS → VIEW FILING →
THURSDAY, OCTOBER 29 · DAILY EDITION
Daily Market Brief — October 29, 2026
Today's market brief is led by NORDEN's strong Q3 results and raised full-year guidance, which is expected to positively impact the stock. Other notable filings include Upwind's $400 million Series C funding and Cactus, Inc.'s strong third-quarter results.
Cactus, Inc. Reports Strong Q3 Results
Cactus, Inc. reported revenue of $430.9 million and net income of $74.1 million, and announced the construction of a new manufacturing facility in the Middle East.
OUR ANALYSIS → VIEW FILING →Actuate Therapeutics Announces Public Offering
The company's public offering of 30,985,900 shares of common stock and warrants will result in net proceeds of approximately $9.96 million, but will also lead to dilution for existing shareholders.
OUR ANALYSIS → VIEW FILING →Upwind Closes $400 Million Series C Funding
Although Upwind's funding is a significant development, it is not directly relevant to Financewire News' stock price.
OUR ANALYSIS → VIEW FILING →Techprecision Corp Extends Loan Maturity Date
The company extended the maturity date of its $4.5 million revolving line of credit loan, which may indicate liquidity concerns or covenant pressure, but the short extension period is not a significant surprise.
OUR ANALYSIS → VIEW FILING →Techlott Inc Enters into Separation Agreement
The agreement with the former Executive Chairman includes a waiver of certain equity and consulting fee rights, but also involves the issuance of new shares which could lead to dilution.
OUR ANALYSIS → VIEW FILING →NeoVolta Inc Files Amended 10-K
The filing is a routine update and does not contain any quantified surprises or significant new developments.
OUR ANALYSIS → VIEW FILING →GridAI Technologies Corp Loans $1.5 Million
The loan to Pronghorn Resources, LLC brings the total loan amount to $5 million, but is not expected to have a significant impact on the stock price.
OUR ANALYSIS → VIEW FILING →AXIS Capital Holdings Discusses Non-GAAP Measures
The filing explains the company's use of non-GAAP financial measures, but does not contain any quantified surprises or significant updates.
OUR ANALYSIS → VIEW FILING →Transcode Therapeutics Initiates Strategic Process
The company is evaluating opportunities to maximize the value of its oncology portfolio, but there is no assurance of a transaction or outcome.
OUR ANALYSIS → VIEW FILING →Get tomorrow's brief
The filings and moves that matter, in your inbox every market day.
Subscribe free →
← All briefs · Earnings today · Analyses · Track record · RSS
AI-generated summaries. Not investment advice — full disclaimer. Impact labels are model estimates; verify before acting.
© 2026 Dutchcode B.V. · Built by
AI-generated summaries. Not investment advice — full disclaimer. Impact labels are model estimates; verify before acting.
© 2026 Dutchcode B.V. · Built by